{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:13:47Z","timestamp":1780445627990,"version":"3.54.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The alkylating agent cyclophosphamide is used in chemotherapy regimens for various type of cancer. However, cyclophosphamide may lead to toxic side effects on the bladder, namely hemorrhagic cystitis, which can cause hematuria, and, potentially, bladder cancer. These effects are caused by acrolein, a byproduct of cyclophosphamide metabolism. In this study, a method to quantify 3-hydroxypropyl mercapturic acid (3-HPMA) in urine was developed. 3-HPMA is a stable metabolite of acrolein that serves as biomarker of acrolein.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Urine samples were collected 4 hours after cyclophosphamide administration and analyzed to determine the risk of hematuria. 3-HPMA was analyzed by reverse-phase LC-MS\/MS using a triple quadrupole electrospray ionization mass spectrometer in the positive-ion mode. The mobile phase was a 90:10 (vol\/vol) mixture of 0.1% formic acid in water and 0.1% formic acid in acetonitrile. Multiple reaction monitoring mode was used, with <jats:italic toggle=\"yes\">m\/z<\/jats:italic> 222.10 \u2192 90.97 for 3-HPMA and 164.10 \u2192 122.02 for the internal standard N-acetyl cysteine (NAC). Samples were prepared by acidification and dilution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The analytical method produced a linear response within the concentration range of 40\u201310,000 ng\/mL. The method was validated in accordance with 2018 FDA guidelines and applied to quantify 3-HPMA in the urine of 40 patients with breast cancer. The measured concentrations ranged from 820.3 to 5596.1 ng\/mg creatinine. Seven patients identified with hematuria had low 3-HPMA concentrations of 4445.824 \u00b1 411.17 ng\/mg creatinine, and 33 patients without hematuria had low 3-HPMA concentrations of 2419.4 \u00b1 1171.8 ng\/mg creatinine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The method was applicable for the quantification of 3-HPMA in human urine. Large variations in 3-HPMA concentrations were found in 40 patients with breast cancer treated with cyclophosphamide, with a significant difference (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05) observed between patients with hematuria and those without hematuria.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000737","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T05:06:28Z","timestamp":1582261588000},"page":"548-553","source":"Crossref","is-referenced-by-count":9,"title":["Quantification of 3-Hydroxypropyl Mercapturic Acid in the Urine of Patients with Breast Cancer to Monitor Cyclophosphamide Toxicity"],"prefix":"10.1097","volume":"42","author":[{"given":"Yahdiana","family":"Harahap","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arry","family":"Yanuar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Muhammad","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Melhan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denni Joko","family":"Purwanto","sequence":"additional","affiliation":[{"name":"Functional Medical Staff of Surgical Oncology, Dharmais Cancer Hospital, Jakarta, Indonesia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"De Jonge","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/17425255.2010.487861","article-title":"Oxazaphosphorines: new therapeutic strategies for an old class of drugs","volume":"6","author":"Giraud","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R4-20230814","first-page":"199","article-title":"Mechanisms of hemorrhagic cystitis","volume":"2","author":"Haldar","year":"2014","journal-title":"Am J Clin Exp Urol."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5455\/jeim.080312.ir.010","article-title":"Chemotherapy-induced hemorrhagic cystitis: pathogenesis, pharmacological approaches and new insights","volume":"2","author":"Ribeiro","year":"2012","journal-title":"J Exp Integr Med."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1089\/neu.2013.2888","article-title":"Determination of urine 3-HPMA, a stable acrolein metabolite in a rat model of spinal cord injury","volume":"30","author":"Zheng","year":"2013","journal-title":"J Neurotrauma."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/chromsci\/48.3.194","article-title":"Development and validation of a direct LC-MS-MS method to determine the acrolein metabolite 3-HPMA in urine","volume":"48","author":"Yan","year":"2010","journal-title":"J Chromatogr Sci."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.chroma.2017.08.030","article-title":"Determination of 3-hydroxypropylmercapturic acid in urine by three column-switching high-performance liquid chromatography with electrochemical detection using a diamond electrode","volume":"1517","author":"Higashi","year":"2017","journal-title":"J Chromatogr A."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bmt.1701355","article-title":"Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients","volume":"22","author":"Al-Rawithi","year":"1998","journal-title":"Bone Marrow Transpl."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"7","DOI":"10.11622\/smedj.2015003","article-title":"Normalisation of urinary biomarkers to creatinine for clinical practice and research\u2014when and why","volume":"56","author":"Tang","year":"2015","journal-title":"Singapore Med J."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/bmc.653","article-title":"Determination of S-phenylmercapturic acid in human urine using an automated sample extraction and fast liquid chromatography-tandem mass spectrometric method","volume":"20","author":"Li","year":"2006","journal-title":"Biomed Chromatogr."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2008.323","article-title":"Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia","volume":"23","author":"Rocha","year":"2009","journal-title":"Leukemia."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.apsb.2012.02.004","article-title":"Oxazaphosphorine bioactivation and detoxification: the role of xenobiotic receptors","volume":"2","author":"Wang","year":"2012","journal-title":"Acta Pharm Sinica B."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:25:14Z","timestamp":1692051914000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000737","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}